Please, please, please change your mind: Yesterday, King Pharmaceuticals lost its fight with Indian generics maker Lupin when a federal appeals court invalidated the patent on Altace. Today, King says it's asking for a rehearing. The court misapplied precedent and relied on factual inaccuracies, the company says.
The high blood pressure remedy was supposed to be safe through October 2008. With sales of $900 million in the 12 months ended June 30, it makes up about one-third of King's revenues--so you can understand the company's consternation. The company had planned to launch a tweaked version of Altace early next year as a sort of trawling net for BP patients tempted to switch to the generic.
- see the release [1] for more info
Related Articles:
King bails on Palatin's FSM program. Report [2]
FDA rejects King's Altace. Report [3]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-king-pharmaceuticals-reports-plan-file-motion-rehearing-and-rehearing-e
[2] http://www.fiercebiotech.com/story/king-bails-palatins-fsm-program/2007-09-10
[3] http://www.fiercebiotech.com/story/also-noted-biomarin-to-raise-267m-fda-rejects-king-s-altace-and-much-more/2006-03-24?utm_source=related&utm_medium=internal